COVID-19

March 30, 2021

Monroe Carell Jr. Children’s Hospital at Vanderbilt selected as trial site for pediatric COVID-19 vaccine

Monroe Carell Jr. Children’s Hospital at Vanderbilt is set to begin a phase 2/3 clinical trial to study the safety and efficacy of the Moderna COVID-19 vaccine in children.

March 19, 2021

COVID-19 and Cancer Consortium study highlights racial disparities, increased mortality for patients facing dual diagnoses

The COVID-19 and Cancer Consortium (CCC19) published new findings in the Annals of Oncology showing heightened mortality and racial disparities for patients with cancer diagnosed with SARS-CoV-2 infection.

March 18, 2021

Study to assess allergic reactions to COVID vaccines

Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.

March 15, 2021

Preterm births in Tennessee decreased during pandemic

Statewide stay-at-home orders put in place as Tennessee fought to control the spread of coronavirus last March were associated with a 14% lower rate of preterm birth, according to a research letter published today in JAMA Pediatrics.

March 12, 2021

Tears of joy, tears of sorrow — College sweethearts, a COVID unit wedding, and a love story that ended too soon

The inside story of how VUMC’s COVID unit staff pulled together to arrange a wedding, and a reminder that not every love story has a happy ending

Contributors to the COVID-19 microbiome study include (front row, from left) Julie Bastarache, MD, Meghan Shilts, MS, MHS, (middle row, from left) Jodell Jackson, PhD, Suman Das, PhD, Angela Jones, MS, (back row, from left) Jonathan Schmitz, PhD, MD, Simon Mallal, MBBS, and Jordan Best, PhD.
March 11, 2021

‘Friendly’ bacteria may impact COVID severity

The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19.